Search the Site

News and views

Stay informed

Home / News and views
News > News Article

18 July 2022

FODO responds to GOC call for evidence and consultation

FODO has responded to the GOC call for evidence on the Opticians Act and consultation on associated GOC policies.

Daniel Hodgson, FODO's head of policy and public affairs, said: "Our response follows an extensive review of the legislation and literature and consultation with members and subject matter experts in health regulation.

"We would like to thank all members who volunteered to participate in our response, whether sharing evidence, attending a workshop or providing feedback on drafts. Your time and expertise have helped shape our response."

The FODO submission says the Opticians Act is a robust and successful piece of patient protection legislation that has stood the test of time - evidenced by high standards, safe adoption of new technologies and how the scope of practice has changed to meet eye health needs.

The evidence FODO shared also demonstrates that because the sight test in the UK is a comprehensive assessment of vision and eye health, it is a significant population and public health benefit. Few countries have an eye care service that is as accessible, safe, and cost-effective as primary eye care in the UK.

After reviewing the evidence, analysing legislation, and horizon scanning, FODO has recommended that the GOC update some of its policies and standards but that there is no evidence-based case, given GOC objectives for this call for evidence and consultation, to amend the Act.

Read the full FODO response

If you have questions about FODO's response or want to discuss any related policy issues, please email [email protected]

Share this page
For more information please contact:


* indicates required
I confirm I would like to receive the following newsletter:

Press enquiries

Media enquiries should be directed to [email protected] or call 020 7298 5151.

We are happy to put you in touch with our expert policy advisers who can comment on a variety of issues.

You can also follow us on Twitter and LinkedIn.